Evolus, the aesthetics company known for Jeuveau®, has announced record-breaking financial results for 2024 and is preparing to disrupt the dermal filler market with the highly anticipated launch of Evolysse™.

While the official launch is expected in Q2 2025 now that they have received FDA approval, Evolus has already begun reaching out to providers, inviting them to join the early access list to be among the first to order these next-generation hyaluronic acid-based fillers.

What is Evolysse™?

Evolysse™ is a new line of dermal fillers developed by Evolus in collaboration with French biomaterials company Symatese. The portfolio consists of five unique formulations designed to address various aesthetic needs, including:

Mid-face volume loss
Nasolabial folds
Lips
Periorbital areas

The first two products in the line, Evolysse™ Form and Evolysse™ Smooth, have undergone a pivotal U.S. clinical trial comparing their efficacy to Restylane-L. The study found that Evolysse™ fillers met primary non-inferiority endpoints while demonstrating superiority over Restylane-L at the six-month mark, with a comparable safety profile. No treatment-related serious adverse events were reported.

How Does Evolysse™ Compare to Existing Fillers?

Evolysse™ aims to set itself apart in the competitive dermal filler market by offering:

Next-generation formulation developed through Symatese’s proprietary technology.
Longer-lasting effects compared to some market competitors, based on clinical data.
Tailored treatment versatility with five distinct formulations for different aesthetic concerns.

While Allergan’s Juvéderm® and Galderma’s Restylane® products dominate the market, Evolus is positioning Evolysse™ as an innovative alternative backed by strong clinical performance and strategic market entry.

Regulatory and Market Timeline

Evolus submitted its final Premarket Approval (PMA) module to the FDA and expects approval within the next 90 days. The U.S. launch is anticipated in Q2 2025, ahead of the previously scheduled timeline. This marks a significant step in Evolus’ strategy to expand beyond neurotoxins and establish itself as a major player in the dermal filler market.

Read the full press release on Business Wire.

Why This Matters for Medspas

The aesthetics industry has seen increasing demand for high-performance fillers that deliver natural-looking, long-lasting results. With Evolysse™, Evolus is aiming to meet this demand by offering a new-generation filler that aligns with modern consumer expectations for facial enhancement.

How to Get Early Access

Evolus has started inviting providers to sign up for priority ordering of Evolysse™ ahead of the official launch. If you’re a medspa owner or injector, this is an opportunity to be among the first to offer these new fillers to your clients.

Visit Evolus’ official provider sign-up page to join the priority list.

Frequently Asked Questions

What is Evolysse™?

Evolysse™ is a new line of dermal fillers by Evolus, developed in collaboration with Symatese, designed for mid-face volume loss, nasolabial folds, lips, and periorbital areas.

How does Evolysse™ compare to Restylane® and Juvéderm®?

Evolysse™ is formulated using Symatese’s proprietary technology and has shown superior results to Restylane-L in clinical trials, offering longer-lasting effects and a tailored treatment approach.